Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid, Hope S. Rugo, Sylvia Adams, Andreas Schneeweiss, Carlos H. Barrios, Hiroji Iwata, Véronique Diéras, Volkmar Henschel, Luciana Molinero, Stephen Y. Chui, Vidya Maiya, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens

    Research output: Contribution to journalArticlepeer-review

    155 Scopus citations

    Fingerprint Dive into the research topics of 'Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

    Medicine & Life Sciences